Tyme Files For U.S. Patent Titled ‘PHARMACEUTICAL COMPOSITIONS AND METHODS’

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210169903%22.PGNR.&OS=DN/20210169903&RS=DN/2021

byBenzinga Newsdesk

June 10, 2021

1 minute read

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210169903%22.PGNR.&OS=DN/20210169903&RS=DN/20210169903

Huntsman Q2 EPS $0.86 Beats $0.80 Estimate, Sales $2.02B Beat $1.86B Estimate

By Benzinga Newsdesk

Today, 11:00 PM

Huntsman (NYSE:HUN) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.80 by 7.5 percent. This is a 714.29 percent increase over losses of $(0.14) per share from the same

HUN

Morgan Stanley Maintains Equal-Weight on Occidental Petroleum, Raises Price Target to $74

By Benzinga Newsdesk

Today, 11:00 PM

Morgan Stanley analyst Devin McDermott maintains Occidental Petroleum (NYSE:OXY) with a Equal-Weight and raises the price target from $73 to $74.

OXY

Hill International Q2 EPS $(0.01) Down From $0.06 YoY, Sales $101.55M Beat $100.70M Estimate

By Benzinga Newsdesk

Today, 11:00 PM

Hill International (NYSE:HIL) reported quarterly losses of $(0.01) per share. This is a 116.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of

HIL

Gilead’s Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients

By Vandana Singh

Today, 11:00 PM

Gilead Sciences Inc’s (NASDAQ:GILD) unit Kite Pharma has announced top-line results from the primary analysis of ZUMA-7 of Yescarta (axicabtagene ciloleucel) compared to…

GILD

Tyme Files For U.S. Patent Titled ‘PHARMACEUTICAL COMPOSITIONS AND METHODS’

Related Posts

Huntsman Q2 EPS $0.86 Beats $0.80 Estimate, Sales $2.02B Beat $1.86B Estimate

Morgan Stanley Maintains Equal-Weight on Occidental Petroleum, Raises Price Target to $74

Hill International Q2 EPS $(0.01) Down From $0.06 YoY, Sales $101.55M Beat $100.70M Estimate

Gilead’s Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients